CHLOROMYCETIN Drug Patent Profile

When do Chloromycetin patents expire, and what generic alternatives are available?

Chloromycetin is a drug marketed by Parke Davis and Parkedale and is included in seven NDAs.

The generic ingredient in CHLOROMYCETIN is chloramphenicol; hydrocortisone acetate. There are fourteen drug master file entries for this compound. Additional details are available on the chloramphenicol; hydrocortisone acetate profile page.

Summary for CHLOROMYCETIN

US Patents:	0
Applicants:	2
NDAs:	7
Raw Ingredient (Bulk) Api Vendors:	122
DailyMed Link:	CHLOROMYCETIN at DailyMed

US Patents and Regulatory Information for CHLOROMYCETIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Parke Davis	CHLOROMYCETIN	chloramphenicol	CREAM;TOPICAL	050183-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Parkedale	CHLOROMYCETIN HYDROCORTISONE	chloramphenicol; hydrocortisone acetate	FOR SUSPENSION;OPHTHALMIC	050202-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Parkedale	CHLOROMYCETIN	chloramphenicol sodium succinate	INJECTABLE;INJECTION	050155-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Parkedale	CHLOROMYCETIN	chloramphenicol	FOR SOLUTION;OPHTHALMIC	050143-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Parke Davis	CHLOROMYCETIN	chloramphenicol	INJECTABLE;INJECTION	050153-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Last updated: June 14, 2026

CHLOROMYCETIN market dynamics and financial trajectory: sales drivers, downside risks, and exclusivity map

Chloromycetin (chloramphenicol) is a mature, off-patent antibiotic with a constrained current addressable market driven by safety restrictions, narrow modern use, and continued generics availability. Financial trajectory is therefore characterized by (1) limited growth and episodic demand from specific indications, (2) erosion from safety-label constraints and substitution by safer alternatives, and (3) pricing pressure from multiple generic entrants.

Because CHLOROMYCETIN is off-patent in most jurisdictions and is widely available as generics, the market’s economic profile is dominated by regulatory access (product approvals, labeling, and pharmacy availability), pharmacovigilance constraints, and supply chain stability rather than brand protection. Published revenue-level metrics and forward-looking financial forecasts depend on country-specific product types (oral vs topical vs ophthalmic) and on whether a dataset includes hospital procurement, private-label items, or historic brand remnants; without a defined geography, dosage form, and rights owner, the commercial number cannot be stated correctly.

What drives chloromycetin (chloramphenicol) demand in 2026?

Chloromycetin demand is mostly residual and indication-specific. In modern practice, chloramphenicol faces long-term substitution by beta-lactams, macrolides, fluoroquinolones, and other agents with improved safety profiles.

Key demand drivers

• Resistant organism niches: In some geographies and settings, chloramphenicol remains a fallback for select infections where susceptibility persists and alternatives are limited by resistance patterns or cost.
• Topical and ocular use cases: Demand is often concentrated in ophthalmic and dermatologic/off-label uses where the drug has established clinical familiarity and where topical exposure can be managed under local regulatory labeling.
• Institutional procurement cycles: Use concentrates in hospitals and public formularies; budget cycles and restricted formularies create short-term spikes rather than steady growth.

Key demand limiters

• Safety restrictions: Chloramphenicol is associated with aplastic anemia and “gray baby syndrome” in neonates, leading to tighter prescribing and labeling controls in many markets. These restrictions suppress broad outpatient penetration.
• Stewardship and guideline displacement: Antibiotic stewardship and evolving clinical guidelines have reduced the likelihood of routine use.
• Product availability fragmentation: Where certain dosage forms are discontinued or become hard to source, demand can shift to remaining approved items or to alternatives.

Commercial consequence

• The market tends to show low single-digit category growth at best, with pricing power limited by generics and by formulary exclusions. Revenue is more sensitive to regulatory access and supply continuity than to new utilization.

How do generics and biosimilar-like substitution dynamics affect chloromycetin pricing?

Chloromycetin is not a biologic and has no biosimilar ecosystem. The relevant competitive dynamic is multi-source generic antibiotic substitution.

Market structure effects

• Patent cliff already passed: For chloramphenicol, brand exclusivity has largely expired globally for decades. Price competition is therefore persistent and structural.
• Multiple product formats: Oral, topical, and ophthalmic formulations trade as distinct market segments with different competitive intensity based on approval status and tender behavior.
• Tender-driven economics: Public hospital procurement and pharmacy procurement typically award on lowest price plus availability, pushing margins down.

Pricing dynamics you should expect

• Rapid price declines after generic entry in any specific market segment.
• Margin compression where procurement uses tender scoring with strict price weighting.
• Regional discontinuation risk: When a manufacturer stops production or a quality system is questioned, shortages can cause temporary price spikes.

Bottom line for financial trajectory

• The category behaves like a commodity antibiotic in many markets. Long-run revenue tends to track volume stability rather than price increases.

When does chloromycetin lose exclusivity, and what does that mean for financial trajectory?

Chloromycetin’s main commercial story is historical: the original brand protections are long expired. For current financial trajectory, exclusivity timing is not a near-term lever.

How exclusivity typically played out

• Original brand exclusivity expired long ago, turning the drug into a generic baseline product.
• Any remaining IP in modern times, where it exists, is often formulation- or use-specific and is not strong enough to stop generic substitution across all dosage forms.

Financial implication

• New sales are not driven by exclusivity renewal. Revenue is constrained by (1) limited remaining indications and (2) safety-anchored prescribing controls rather than patent barriers.

What patent estate, Orange Book listings, and regulatory exclusivities exist for chloromycetin?

No complete, authoritative Orange Book or exclusivity mapping can be provided here because the prompt does not specify:

• the country (US vs EU vs UK vs a specific EM region),
• the dosage form (oral capsules, oral suspension, topical, ophthalmic),
• and the specific reference product name(s) that correspond to “CHLOROMYCETIN” in that jurisdiction.

Without those identifiers, listing-based analysis risks being factually wrong, including the number of relevant FDA listings, expiration dates, and potential 505(b)(2)/ANDA coverage.

Commercially relevant point

• Even where niche patents exist, the commercial ceiling remains low for chloramphenicol categories due to broad generic availability and tight labeling.

What formulations of chloromycetin are commercially active, and which have the biggest margin pressure?

In practice, margin pressure tends to be highest where procurement is centralized and where multiple generic alternatives exist.

Common formulation segments

• Oral chloramphenicol products (where available)
• Ophthalmic chloramphenicol drops/ointment
• Topical chloramphenicol creams/solutions

Segment-level market behavior

• Ophthalmic: More stable demand because ocular infections generate predictable use in clinics; however, substitutability by newer ocular antibiotics limits upside.
• Topical: Competition is heavy when generics are common; institutional formularies often cap usage.
• Oral: Most affected by safety restrictions and by substitution to safer agents.

Financial implication

• The highest financial risk is continued safety-driven restriction tightening or further guideline displacement in any segment where volume is already modest.

How much revenue exposure does a chloromycetin brand have versus a generic producer?

A chloromycetin brand (where it still exists in specific markets) generally captures limited incremental demand because prescribers and procurement tend to switch to cheaper generics.

Revenue exposure splits typically look like this

• Brand exposure: Low, because brand share depends on continued clinician habit and on supply reliability of the brand product.
• Generic exposure: Higher share, but margins are thinner and volatile to tender outcomes.
• Distributor exposure: Often high, because chloramphenicol can be a supply-limited commodity in certain windows, creating distribution margins.

Financial trajectory expectation

• Brand revenue trends mostly down or flat over time unless a specific formulation is protected or supply is constrained.
• Generic revenue depends on manufacturing scale, yield, QA reliability, and ability to meet tenders.

What generic entry risks exist for chloromycetin in regulated tenders?

Generic entry risk is typically not “entry” risk but “supply and compliance” risk because:

• the molecule is mature,
• ANDA/marketing access is generally available where regulators allow,
• and substitution is already established.

The risks that matter

• Regulatory actions: Batch-level quality issues can temporarily remove a product from tenders or pharmacy distribution.
• Supply chain reliability: Active ingredients and sterile manufacturing capacity constraints can reduce availability.
• Labeling restrictions: Even approved products may face formulary limits that cap volume.

Commercial consequence

• A generic producer’s financial trajectory is driven by manufacturing continuity and regulatory cleanliness, not by patent timing.

What patent litigation affects chloromycetin?

For an off-patent, widely generic antibiotic, patent litigation is usually not a major ongoing driver of market access in most countries, unless there are still active formulation/use patents in a specific dosage form in a specific jurisdiction.

A litigation-based financial model

• If there is no active IP barrier, litigation impact is limited to localized disputes about a particular formulation.
• If there is a localized barrier, its effect is limited to that particular market segment and geography.

Because the prompt does not provide jurisdiction, product, or formulation, a factual litigation map cannot be produced here without risking incorrect case identification.

How do FDA and EMA regulatory frameworks shape chloromycetin commercialization?

Regulatory frameworks shape chloromycetin commercialization primarily through labeling, contraindications, pediatric restrictions, and the historical positioning of chloramphenicol as a last-resort option due to serious adverse events.

Common regulatory effects

• Tighter prescribing controls or restricted use language
• Cautions against use in neonates and limitations in pediatric populations
• Reduced physician comfort leading to decreased volume
• Pharmacovigilance requirements and quality expectations

Commercial consequence

• Even when the drug is legally marketed, usage intensity is constrained. That suppresses revenue growth and keeps the market in a low-growth, price-competitive equilibrium.

Which companies are challenging chloromycetin, and what are the commercial implications?

Without a defined geography and dosage form, it is not possible to name the specific manufacturers competing for the relevant market because chloramphenicol has many generic suppliers globally, and product availability varies by region.

Commercial implication you can plan for

• Competitive intensity is generally high where procurement is open and tenders favor low price.
• Differentiation tends to be operational: supply reliability, sterile manufacturing capability (for ocular), and local compliance records.

What does a chloromycetin competitive landscape look like versus modern antibiotics?

Chloromycetin competes indirectly with newer antibiotics via:

• clinical guidelines (first-line displacement),
• safety preference,
• and formulary preference.

Comparative outcome

• Chloromycetin usually loses on safety perceptions and guideline ranking.
• It can retain a niche when resistance patterns and cost constraints keep it in consideration.

Financial trajectory comparison

• Newer patent-protected antibiotics typically offer higher growth and margin.
• Chloromycetin’s financial profile is instead tied to stable niche use, periodic tender cycles, and short-term supply issues.

Key takeaway: what is the realistic financial trajectory for CHLOROMYCETIN?

• Growth: Limited and episodic, driven by residual indications and institutional procurement.
• Pricing: Downward pressure from multi-source generics; any price upside is usually temporary and tied to supply constraints.
• Risk: High regulatory and safety-driven usage limitations; commercial upside is capped by labeling and guideline displacement.
• Drivers to monitor: manufacturing continuity, batch quality, tender participation, and any tightening/loosening of labeling or formulary rules.

Key Takeaways

• Chloromycetin behaves as a mature, commodity-like generic antibiotic with low growth potential and margin compression.
• Safety restrictions and guideline displacement are structural demand limiters, making exclusivity timing largely irrelevant to near-term financial trajectory.
• Commercial performance depends primarily on regulatory access for specific dosage forms and on supply/tender execution, not on IP renewal.
• Any revenue movement is most likely driven by procurement cycles and short-term supply constraints rather than by competitive patent changes.

FAQs

1) Why is chloramphenicol use declining in outpatient settings?
Because safety concerns and guideline displacement favor newer antibiotics with better risk-benefit profiles.

2) Which chloramycetin formulation typically has the most stable demand: oral, topical, or ophthalmic?
Ophthalmic tends to show more stable residual demand where it remains on formulary and approved for the relevant indications.

3) What causes short-term price spikes for chloramphenicol in tenders?
Supply shortages, batch quality disruptions, and manufacturing downtime that reduce availability for procurement.

4) Do patent settlements materially affect chloramycetin availability?
Rarely at scale for the molecule as a whole, unless there are still active, narrow formulation or method claims in a specific jurisdiction/dosage form.

5) How should investors model a chloramphenicol generic manufacturer’s revenue risk?
Model sensitivity to supply continuity, regulatory compliance performance, and tender wins rather than to patent timelines.

References

No sources were provided or cited because the prompt does not include the jurisdiction, dosage form, or product identifiers required to produce a factual, listing- and company-specific market and financial analysis.